A major piece of news suddenly shattered the tranquility of the night.
Everyone's phone was bombarded with Toutiao, all about the same thing.
"The National Medical Products Administration has demanded a thorough investigation into the carcinogenicity of Sanofi's Antihypertensive Drug."
"Sanofi's Irbesartan was found to contain Nitrosamines, and the company was ordered to recall the problematic drug."
"The Drug Administration Bureau has taken decisive action, forcibly recalling problematic drugs or imposing hefty fines."
Netizens were stunned when they saw these news reports.
These past few days they've been vehemently criticizing those double-standard foreign companies online.
Unexpectedly, the Drug Administration Bureau acted swiftly and decisively in such a short time to deal with the double standards applied to problematic drugs.
I suddenly felt a sense of pride and triumph.
Upon opening the trending topics, the news was strongly worded, and the detailed content was even more satisfying to read.
"Regarding the issue of Nitrosamines being detected in Irbesartan tablets, a drug sold globally by the Gaul Country pharmaceutical company Sanofi, the State National Medical Products Administration attaches great importance to this matter and immediately launched an investigation into Sanofi's China branch, and will handle the matter in accordance with the law."
"The Beijing Drug Administration Bureau immediately organized personnel to conduct random inspections of drugs sold by Sanofi. Preliminary investigation and analysis revealed that Nitrosamines were detected in Sanofi's Anbowei Antihypertensive Drug, which was caused by a process problem during the company's production."
"The National Medical Products Administration has taken action against this serious safety incident, requiring Sanofi China to immediately recall the problematic batch of drugs and to handle related compensation and personnel lawsuits in accordance with the law."
"Once all the drugs have been recalled, an administrative fine of twenty times the amount involved will be imposed."
"This shows that any pharmaceutical manufacturer in China must prioritize product quality and consciously abide by my country's laws, regulations and relevant technical specifications."
"Whenever a product defect or quality problem occurs, the company involved must take recall measures, report to the drug regulatory authorities, and proactively disclose information to the public. Any drugs recalled abroad must be recalled simultaneously in China."
"The National Drug Administration Bureau will further strengthen its supervision, keep abreast of recall information from drug regulatory agencies in various countries, and take strict regulatory measures against drug manufacturers that fail to report recalls or fail to do so in a timely manner, up to and including suspending the production and sale of drugs in China."
Seeing this outcome in the news, netizens were all shocked.
This marks the first time the National Medical Products Administration has publicly and forcefully stated its position on pharmaceutical companies operating in China.
This demonstrates the government's determination to strictly regulate drug safety.
Every word exudes a palpable sense of murderous intent.
The netizens were speechless for a long time before suddenly cheering.
"The General Administration is brilliant! Well done!"
"Return the problematic medication! Return it! Return it!"
"Serves you right for your double standards! You were so stubborn and refused to recall them, but now you've been suppressed by the iron fist, hahaha!"
"Punish them! Punish them severely! Don't hold back, punish them until it hurts!"
"Are there any problems with the other Antihypertensive Drug? We should check those too."
"I'll stick with Three Purities for Antihypertensive Drug from now on; it's more reassuring to use it."
"Support! This must be investigated and punished severely according to the law!"
"I just checked the State Drug Administration Bureau's website. There have been quite a few drug recalls in the past year, most of which involved domestic pharmaceutical companies. This time it's finally the turn of foreign companies."
"Since the Changsheng Vaccine incident, the pharmaceutical industry has been paying close attention to drug safety issues, and the authorities have responded immediately."
"I hope other industries can follow suit and properly deal with these double-standard foreign companies. I remember the last time Magnum Ice Cream had double standards, it seems there was no follow-up."
"Then we'll have to contact the State Administration for Market Regulation. Maybe the double standard issue with the ice cream isn't that serious. After all, it's just falsifying the ingredient list, not causing anyone's death. It certainly wouldn't attract as much attention as drugs causing cancer."
"Sigh, now I'm completely at ease about drug safety. When will they also crack down on food safety issues so that everyone can eat with even more peace of mind?"
"It's hard to say. Given the domestic market environment, lessons won't be learned until problems arise."
"They don't learn from their mistakes. They still sell pickled cabbage made from foot skin. The only thing to do is vote with your feet and refuse to buy it."
"That's right. Whether it's medicine or food, we should buy high-quality domestic products from now on. We should make sure that double-standard foreign companies either fail completely or are on their way to failure."
At the same time, Sanofi officially apologized to the entire internet and announced a recall of the problematic batches of Antihypertensive Drug.
"We are sorry for letting everyone down. We sincerely apologize to all the Chinese people for the mistakes we have made."
"We will officially recall all problematic drugs sold in the China market. After inspection, the problematic batches are xxxx and xxxx. Patients who have purchased these batches of drugs are requested to immediately return to their original hospital, and the payment will be refunded to the original payment method."
"From now on, we will take a responsible attitude towards public health, carefully investigate the causes of problems, improve quality management, implement various risk control measures, eliminate safety hazards, and ensure the quality of products on the market."
"If you have any questions, please don't hesitate to contact us as soon as possible to discuss how to handle the situation. Thank you!"
This time, Sanofi dared not close the comments section again, and netizens flocked in, venting their emotions to their hearts' content.
"You're so stubborn, but can you outdo the iron fist of the people?"
"I hope the authorities will remain this firm in the future and strongly suppress foreign companies that apply double standards."
"I'm on the side of the Drug Administration Bureau this time. @Market Supervision Bureau, you should take a good look at how they did it!"
"Learn from them, Pfizer, @Johnson & Johnson, Merck, Roche, @Maple Canada Goose, Nike, @Two Samsung, Toyota, Volkswagen, IKEA, Magnum."
Netizens tagged all the foreign companies that were applying double standards in the comments section of this announcement.
They also kept going to their official homepage to leave comments.
For a moment, all the foreign companies were terrified and trembling at the sight of this situation.
They were both relieved that they weren't the ones being sacrificed, and inwardly they wailed.
Is the China market about to undergo a dramatic transformation?
Is this the authorities making an example of someone to warn others?
Does this mean that any problems that arise in the future will be subject to strict investigation?
Upon thinking of this, all the senior executives of foreign companies in China felt a chill run down their spines, as if a cold wind was blowing through them.
******
After Sanofi was made an example of, Drug Administration Bureau in various cities began to intensify their efforts to conduct random inspections of drugs on the market and test for drug quality issues.
Other pharmaceutical companies have also responded by strengthening the quality control of their own drugs.
Suddenly, a climate of fear and uncertainty prevailed, and the number of imported Antihypertensive Drug drugs on the market plummeted.
In this context, the Antihypertensive Drug launched by Three Purities were almost driven into the market by a strong force, instantly filling the vacuum that had suddenly appeared in the market.
The Drug Administration Bureau has also figured things out through the Sanofi case.
Relying solely on pharmaceutical companies to voluntarily report problems and initiate recalls is likely insufficient. Strengthening supervision and imposing severe penalties are necessary to achieve the desired effect.
Generally speaking, after adverse reactions occur with a drug, the company should conduct a safety evaluation, choose to add a black box to warn of the risk, or restrict the use of the drug to certain groups. If the risks of the drug outweigh the benefits, it needs to be recalled.
Recalls must be differentiated according to different situations. If there is a problem with the drug formulation or medical device, or if the product itself is defective, then all products must be recalled.
If a non-systematic quality problem occurs in a certain production or transportation stage, then only that batch of products needs to be recalled.
Because there are many types of drugs, regulatory authorities cannot have a comprehensive grasp of all adverse drug reactions in a timely manner, and mainly rely on companies to report them proactively.
Adverse drug reaction monitoring is an upstream step in drug recall and should theoretically play a major role.
Drug recalls are the last line of defense for drug safety.
In the Eagle Country, 60% of adverse drug reaction reports are proactively submitted by companies, while in China, the opposite is true.
The proportion of adverse drug reaction reports from domestic pharmaceutical companies is only a mere 25%.
If adverse drug reaction information is not reported in a timely manner, then the subsequent drug recall process will inevitably be lacking.
To ensure drug safety, not only is it necessary to strengthen supervision, but companies themselves must also be able to properly balance the interests of the company with those of the patients.
This incident has once again drawn the attention of policymakers to the issue of drug safety.
The Drug Administration Bureau's swift action this time undoubtedly demonstrates their attitude and determination.